PANVAC vaccines containing transgenes for MUC1, CEA, and three T-cell costimulatory molecules (B7.1, LFA-3, and ICAM-1) have also been tested in a clinical trial with metastatic BC patients (73). This evidence concerns the gene MUC1 and breast cancer.